[go: up one dir, main page]

MX2014008146A - Constructos de mhc parciales y metodos de uso. - Google Patents

Constructos de mhc parciales y metodos de uso.

Info

Publication number
MX2014008146A
MX2014008146A MX2014008146A MX2014008146A MX2014008146A MX 2014008146 A MX2014008146 A MX 2014008146A MX 2014008146 A MX2014008146 A MX 2014008146A MX 2014008146 A MX2014008146 A MX 2014008146A MX 2014008146 A MX2014008146 A MX 2014008146A
Authority
MX
Mexico
Prior art keywords
domain
methods
mhc class
polypeptide
disclosed
Prior art date
Application number
MX2014008146A
Other languages
English (en)
Inventor
Arthur A Vandenbark
Gregory G Burrows
Roberto Meza-Romero
Gil Benedek
Shayne Andrew
Jeffery Mooney
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of MX2014008146A publication Critical patent/MX2014008146A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Se describen en la presente polipéptidos de dominio a1 del complejo de histocompatibilidad mayor (MHC) clase II aislados y métodos de uso. En algunas modalidades, el polipéptido aislado comprende o consiste de un polipéptido de dominio a1 (o porción del mismo) del MHC clase II y no incluye un dominio a2, ß1 o ß2 del MHC clase II. Los polipéptidos de dominio a1 del MHC clase II descritos son de uso en el tratamiento o inhibición de trastornos en un sujeto, tales como trastornos inflamatorios y/o autoinmunes. También se describen métodos para evaluar la eficacia del tratamiento u optimizar el tratamiento de un sujeto con un polipéptido que incluye un polipéptido de dominio a1 (o porción del mismo) del MHC clase II o un polipéptido que incluye un dominio a1 y dominio ß1 del MHC clase II (tal como un RTL ß1a1).
MX2014008146A 2012-01-06 2013-01-04 Constructos de mhc parciales y metodos de uso. MX2014008146A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584045P 2012-01-06 2012-01-06
PCT/US2013/020287 WO2013103816A1 (en) 2012-01-06 2013-01-04 Partial mhc constructs and methods of use

Publications (1)

Publication Number Publication Date
MX2014008146A true MX2014008146A (es) 2016-02-03

Family

ID=47561855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008146A MX2014008146A (es) 2012-01-06 2013-01-04 Constructos de mhc parciales y metodos de uso.

Country Status (11)

Country Link
US (1) US20150044245A1 (es)
EP (1) EP2800582A1 (es)
JP (1) JP6364352B2 (es)
KR (1) KR20140114859A (es)
CN (1) CN104105503A (es)
AU (1) AU2013207489A1 (es)
BR (1) BR112014016652A2 (es)
CA (1) CA2860678A1 (es)
MX (1) MX2014008146A (es)
RU (1) RU2014132426A (es)
WO (1) WO2013103816A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242393C1 (ru) * 2003-05-12 2004-12-20 Производственное республиканское унитарное предприятие "Минский автомобильный завод" Механизм опрокидывания кабины
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
WO2015051330A1 (en) * 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II α1 DOMAINS
EP3052138A4 (en) * 2013-10-03 2017-04-12 Oregon Health & Science University Treatment of ischemic stroke with dr 1-mog-35-55
US10525101B2 (en) 2015-10-23 2020-01-07 Oregon Health & Science University Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
US20170196957A1 (en) 2016-01-08 2017-07-13 Oregon Health & Science University Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer
US20190248867A1 (en) * 2016-07-01 2019-08-15 Loma Linda University Myelin oligodendrocyte glycoprotein-specific peptide for the treatment or prevention of multiple sclerosis
EP3837271A4 (en) * 2018-08-14 2022-06-15 Board of Regents, The University of Texas System SINGLE MOLECULE SEQUENCING PEPTIDES BOUND TO THE MAIN HISTOCOMPATIBILITY COMPLEX
WO2020072992A1 (en) 2018-10-05 2020-04-09 Oregon Health & Science University Recombinant polypeptides comprising modified mhc class ii drα1 domains and methods of use
JP2023504172A (ja) * 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
DE102020109447A1 (de) * 2020-04-03 2021-10-07 Jacobs University Bremen Ggmbh Synthetisches mhc-klasse-ii-protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
JP3603374B2 (ja) * 1995-04-14 2004-12-22 東レ株式会社 融合蛋白質およびその融合蛋白質を固定化した材料
ATE272070T1 (de) * 1996-08-16 2004-08-15 Harvard College Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
EP1017721B1 (en) * 1997-09-16 2009-02-25 Oregon Health and Science University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
EP1054984A1 (en) * 1998-02-19 2000-11-29 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
CA2537759C (en) 2003-09-05 2015-03-24 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US7576183B2 (en) * 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
EP1877440A4 (en) 2005-03-18 2009-07-29 Univ Oregon Health & Science RECOMBINANT MHC MOLECULES SUITABLE FOR MANIPULATING ANTIGEN-SPECIFIC T CELLS
US8491913B2 (en) 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
US20110008382A1 (en) 2009-03-07 2011-01-13 Burrows Gregory G Compositions and methods using recombinant MHC molecules for the treatment of uveitis

Also Published As

Publication number Publication date
WO2013103816A1 (en) 2013-07-11
EP2800582A1 (en) 2014-11-12
WO2013103816A8 (en) 2014-06-26
AU2013207489A8 (en) 2014-09-18
BR112014016652A2 (pt) 2019-09-24
AU2013207489A1 (en) 2014-08-28
RU2014132426A (ru) 2016-02-27
US20150044245A1 (en) 2015-02-12
JP2015505315A (ja) 2015-02-19
CN104105503A (zh) 2014-10-15
CA2860678A1 (en) 2013-07-11
JP6364352B2 (ja) 2018-07-25
KR20140114859A (ko) 2014-09-29

Similar Documents

Publication Publication Date Title
MX2014008146A (es) Constructos de mhc parciales y metodos de uso.
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
SG10201803780UA (en) Methods and compositions for sustained immunotherapy
AU326418S (en) Steamer with cover
PH12013500713A1 (en) Antitussive compositions comprising memantine
AU330117S (en) Steamer with cover
AU323335S (en) Funnel
NZ601065A (en) Wnt antagonists and methods of treatment and screening
AU335240S (en) Cover
EA201691314A1 (ru) Терапевтические способы и композиции
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MX2016007960A (es) Composiciones y metodos para reducir los alegernos de gato en el medio ambiente.
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
TR201909824T4 (tr) Burç düzenekleri ve ilgili yöntemler.
CA138414S (en) Door for animal housing unit
AU335860S (en) Trimming device
GB0818080D0 (en) Immunogenic peptides
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
McIntosh et al. CC: DA/M/1338-1356 Minutes of the meeting held at the 2016 ALA Midwinter Meeting in Boston, Massachusetts January 9 and 11, 2016
AU344393S (en) Guitar body with collage of concert tickets
AU320724S (en) Protective cover